Related Experiment Video
Updated: May 28, 2026
09:51
The Transition to an Anterior-Based Muscle Sparing Approach Improves Early Postoperative Function but is Associated with a Learning Curve
Published on: September 7, 2022
Narrowed indications improve outcomes for hip resurfacing arthroplasty
Aaron J Johnson1, Michael G Zywiel, Hassan Hooper
1Rubin Institute for Advanced Orthopedics Center for Joint Preservation and Replacement, Sinai Hospital of Baltimore, Baltimore, Maryland 21215, USA.
Bulletin of the NYU Hospital for Joint Diseases
|November 1, 2011
Summary
Hip resurfacing arthroplasty shows excellent outcomes, especially in young males with large femoral heads. Strict patient selection criteria, focusing on osteoarthritis and avoiding certain conditions, significantly improved implant survival rates.
Area of Science:
- Orthopedic Surgery
- Biomaterials Science
- Clinical Outcomes Research
Background:
- Hip resurfacing arthroplasty (HRA) offers excellent clinical outcomes.
- Patient selection criteria for HRA remain a subject of debate.
- Optimizing indications may enhance HRA success and reduce complications.
Purpose of the Study:
- To evaluate HRA results from an experienced surgeon.
- To determine if implant survival and complication rates differ based on patient demographics.
- To refine patient selection criteria for HRA.
Main Methods:
- Retrospective review of 311 HRAs (minimum 5-year follow-up).
- Comparison with 93 HRAs (96 hips) using updated selection criteria.
- Analysis of outcomes based on patient age, diagnosis, and femoral component size.
Main Results:
- 10 failures (3% revision rate) in the initial cohort vs. 0 failures in the second cohort.
- Higher revision rates observed in patients with osteonecrosis or rheumatoid arthritis.
- Favorable outcomes (no revisions) in young patients (<50 years) with osteoarthritis and large femoral head sizes (>50 mm).
Conclusions:
- Refined patient selection criteria, particularly for young males with large femoral heads, enhance HRA survivorship.
- HRA can achieve predictable, excellent implant survival in carefully selected patient subgroups.
- HRA may not be universally applicable but offers a viable option for specific patient profiles.